← Zurück zum Screener

Prelude Therapeutics

PRLD Micro Cap

Healthcare · Biotechnology

Aktualisiert: Apr 5, 2026, 17:43 UTC

$3.46
+0.29% heute
52W: $0.61 – $4.22
52W Low: $0.61 Position: 78.9% 52W High: $4.22

Kennzahlen

P/E Ratio
—
Kurs/Gewinn-Verhältnis
Forward P/E
—
Erwartetes KGV
P/S Ratio
17.92x
Kurs/Umsatz-Verhältnis
EV/EBITDA
—
Unternehmenswert/EBITDA
Dividendenrendite
—
Jährl. Dividendenrendite
Market Cap
$217.5M
Marktkapitalisierung
Umsatzwachstum
41%
YoY Umsatzwachstum
Gewinnmarge
—
Nettomarge
ROE
-99.45%
Eigenkapitalrendite
Beta
0.71
Marktsensitivität
Short Interest
18.97%
% der Aktien leerverkauft
Ø Volumen
342,039
Durchschn. Tagesvolumen

Bewertungs-Analyse

Signal
N/A
vs. S&P 500 Ø KGV (24.7x)
Analysten-Konsens
None
3 Analysten
Ø Kursziel
$5.17
+49.33% Upside
Kursziel Spanne
$4.50 – $6.00

Über das Unternehmen

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Sektor: Healthcare Branche: Biotechnology Land: United States Mitarbeiter: 79 Börse: NMS

Trading-Daten

50-Day MA: $2.73
200-Day MA: $1.73
Volumen: 105,675
Ø Volumen: 342,039
Short Ratio: 6.52
Kurs/Buchwert: 4.16x
Verschuldung/EK: 25.92x
Free Cash Flow: $-23,872,250

Wo kann ich Prelude Therapeutics kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.

Nach oben scrollen